Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Intervalo de ano de publicação
1.
Fetal Diagn Ther ; 50(2): 136-142, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36996799

RESUMO

INTRODUCTION: Cystic fibrosis (CF) is a potentially severe disease. The development of new therapies with cystic fibrosis transmembrane conductance regulator (CFTR) modulators has been a great advance in the management of this condition because they improve the function of the faulty CFTR protein rather than palliate its consequences. CFTR modulator therapy improves pancreatic and lung function and, therefore, quality of life, with greater benefits the sooner treatment is started. For this reason, the use of these therapies is being approved for increasingly younger patients. Only two cases of pregnant women taking CFTR modulator therapy with CF fetuses have been reported, suggesting that it could resolve meconium ileus (MI) prenatally and delay/prevent other consequences of CF. CASE PRESENTATION: We report a case of a healthy pregnant patient who underwent CFTR modulator therapy with elexacaftor-tezacaftor-ivacaftor (ETI) in order to treat her fetus with CF (F508del homozygous CFTR mutation) and MI. Ultrasound findings suggestive of MI were observed at 24 weeks. Both parents were tested for CFTR mutations, and both were carriers of the F508del CFTR mutation. The fetus was diagnosed with CF by amniocentesis at 26+2 weeks. Maternal ETI therapy was initiated at 31+1 weeks, and no dilated bowel was observed at 39 weeks. There were no signs of bowel obstruction after birth. Maternal ETI treatment was continued during breastfeeding, with normal liver function. Immunoreactive trypsinogen in the newborn was 58.1 ng/mL, sweat chloride test was 80 mmol/L, and fecal elastase on the second day of life was 58 µg/g. CONCLUSION: Prenatal ETI treatment, as well as during breastfeeding, could solve, prevent, and/or delay CF complications.


Assuntos
Regulador de Condutância Transmembrana em Fibrose Cística , Fibrose Cística , Humanos , Gravidez , Recém-Nascido , Feminino , Regulador de Condutância Transmembrana em Fibrose Cística/genética , Fibrose Cística/complicações , Fibrose Cística/tratamento farmacológico , Fibrose Cística/genética , Qualidade de Vida , Mutação , Feto/metabolismo
3.
Arch. argent. pediatr ; 114(4): e264-e267, ago. 2016. ilus
Artigo em Espanhol | LILACS, BINACIS | ID: biblio-838255

RESUMO

La histiocitosis de células de Langerhans es una enfermedad infrecuente en el lactante y su presentación como una adenitis cervical aislada sin otra sintomatología es excepcional en estos pacientes. Se describe el caso de una lactante de 3 meses de edad que presentaba una tumoración cervical en el ángulo mandibular derecho, con mala respuesta al tratamiento antibiótico. Se realizó una punción-aspiración con aguja fina, que confirmó el diagnóstico de histiocitosis de células de Langerhans. El estudio de extensión no mostró afectación sistémica. Debe considerarse la histiocitosis de células de Langerhans en el diagnóstico diferencial de una masa cervical subaguda de evolución tórpida en los lactantes de corta edad y se debe plantear la realización de una punción-aspiración con aguja fina de manera precoz para establecer el diagnóstico.


Langerhans cell histiocytosis in infants is a rare condition, and presentation as an isolated cervical adenitis is exceptional at this age. We describe the case of a 3-month-old female infant presenting with a neck mass in the right mandibular angle with poor response to antibiotic treatment. Fine needle aspiration was performed and confirmed the diagnosis of Langerhans cell histiocytosis with complementary tests showing no features of systemic involvement. Langerhans cell histiocytosis should be considered in the differential diagnosis of subacute neck masses with poor outcome in infants and physicians should consider performing a fine needle aspiration to establish the diagnosis.


Assuntos
Humanos , Feminino , Lactente , Histiocitose de Células de Langerhans/diagnóstico , Histiocitose de Células de Langerhans/complicações , Linfadenite/etiologia , Pescoço
4.
Arch Argent Pediatr ; 114(4): e264-7, 2016 Aug 01.
Artigo em Espanhol | MEDLINE | ID: mdl-27399030

RESUMO

Langerhans cell histiocytosis in infants is a rare condition, and presentation as an isolated cervical adenitis is exceptional at this age. We describe the case of a 3-month-old female infant presenting with a neck mass in the right mandibular angle with poor response to antibiotic treatment. Fine needle aspiration was performed and confirmed the diagnosis of Langerhans cell histiocytosis with complementary tests showing no features of systemic involvement. Langerhans cell histiocytosis should be considered in the differential diagnosis of subacute neck masses with poor outcome in infants and physicians should consider performing a fine needle aspiration to establish the diagnosis.


La histiocitosis de células de Langerhans es una enfermedad infrecuente en el lactante y su presentación como una adenitis cervical aislada sin otra sintomatología es excepcional en estos pacientes. Se describe el caso de una lactante de 3 meses de edad que presentaba una tumoración cervical en el ángulo mandibular derecho, con mala respuesta al tratamiento antibiótico. Se realizó una punción-aspiración con aguja fina, que confirmó el diagnóstico de histiocitosis de células de Langerhans. El estudio de extensión no mostró afectación sistémica. Debe considerarse la histiocitosis de células de Langerhans en el diagnóstico diferencial de una masa cervical subaguda de evolución tórpida en los lactantes de corta edad y se debe plantear la realización de una punción-aspiración con aguja fina de manera precoz para establecer el diagnóstico.


Assuntos
Histiocitose de Células de Langerhans/diagnóstico , Feminino , Histiocitose de Células de Langerhans/complicações , Humanos , Lactente , Linfadenite/etiologia , Pescoço
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA